kyv-101
Cell therapyexperimental
Clinical trial activity
6 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Feb 29, 2024 (NCT06152172)
Timeline
Indications
Studied for
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · Phase 1
- Dermatomyositis · Phase 1
- Multiple Sclerosis · Phase 2
- Multiple Sclerosis, Chronic Progressive · Phase 2
- Myasthenia Gravis · Phase 2
- Myositis · Phase 1
- Nephritis · Phase 1
- Scleroderma, Diffuse · Phase 1
- Scleroderma, Systemic · Phase 1/Phase 2
- Sclerosis · Phase 1/Phase 2
- Vasculitis · Phase 1/Phase 2
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06590545 | Phase 1/Phase 2 (Phase 2) | Jan 31, 2025 | Humboldt University, Kyverna Therapeutics |
| NCT06384976 | Phase 2 | Sep 30, 2024 | Kyverna Therapeutics |
| NCT06193889 | Phase 2 | Aug 28, 2024 | Kyverna Therapeutics |
| NCT06400303 | Phase 1/Phase 2 (Phase 2) | Aug 6, 2024 | Kyverna Therapeutics |
| NCT06298019 | Phase 1 | Apr 30, 2024 | Stanford University |
| NCT06152172 | Phase 1 | Feb 29, 2024 | Kyverna Therapeutics, University of Pennsylvania |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kyverna Therapeutics | For profit | 5 | 3 | 2 | 2024 |
| Humboldt University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Stanford University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Pennsylvania | Academic/Hospital | 1 | 1 | 1 | 2024 |
4 organizations
Page 1 / 1